Rabeprazole
- Generic Name
- Rabeprazole
- Brand Names
- Aciphex, Pariet
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21N3O3S
- CAS Number
- 117976-89-3
- Unique Ingredient Identifier
- 32828355LL
- Background
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
- Indication
For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
- Associated Conditions
- Duodenal Ulcer, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Heartburn, Helicobacter Pylori Infection, Non-erosive Reflux Esophagitis Disease (NERD), Vomiting, Zollinger-Ellison Syndrome, Develop NSAID-induced gastric ulcers, Erosive reflux esophagitis
- Associated Therapies
- -
Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole
- Conditions
- Interventions
- First Posted Date
- 2016-12-08
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Xijing Hospital of Digestive Diseases
- Registration Number
- NCT02986685
- Locations
- 🇨🇳
Xijing Hosipital of Digestive Disease, Xi'an, Shaanxi, China
Effect of Proton Pump Inhibitors on Palpitations
- Conditions
- Interventions
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2018-03-13
- Lead Sponsor
- Jordan Collaborating Cardiology Group
- Target Recruit Count
- 30
- Registration Number
- NCT02826408
- Locations
- 🇯🇴
Istishari Hospital, Amman, Jordan
Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2016-03-04
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT02699710
- Locations
- 🇬🇧
Quotient Clinical Ltd, Clinical Research Unit, Nottingham, United Kingdom
A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2016-01-14
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT02655614
- Locations
- 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸Mayo Clinic Hospital - Florida, Jacksonville, Florida, United States
🇺🇸Forbes Norris Mda/als Ctr; Research Center, San Francisco, California, United States
Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD.
- First Posted Date
- 2015-12-23
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Il-Yang Pharm. Co., Ltd.
- Target Recruit Count
- 176
- Registration Number
- NCT02638584
- Locations
- 🇰🇷
HALLYM UNIVERSITY MEDICAL CENTER, Chuncheon Sacred Heart Hospital, Chuncheon, Gangwon-do, Korea, Republic of
PPI And Food Effect Study For PF-06463922 In Healthy Volunteers
- First Posted Date
- 2015-10-06
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 27
- Registration Number
- NCT02569554
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
Proton Pump Inhibitors and Risk of Community-acquired Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2015-09-22
- Target Recruit Count
- 4238504
- Registration Number
- NCT02555852
- Locations
- 🇨🇦
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants
- First Posted Date
- 2015-06-18
- Last Posted Date
- 2016-01-11
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT02475161
To Evaluate Efficacy and Safety of Z-215 in Erosive Esophagitis
- Conditions
- Interventions
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Zeria Pharmaceutical
- Target Recruit Count
- 503
- Registration Number
- NCT02463643
A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 517
- Registration Number
- NCT02135107
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.